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IMPORTANCE On the basis of observational studies, the use of thiazide diuretics for the
treatment of hypertension is associated with reduced fracture risk compared with nonuse.
Data from randomized clinical trials are lacking.
OBJECTIVE To examine whether the use of thiazide diuretics for the treatment of
hypertension is associated with reduced fracture risk compared with nonuse.
DESIGN, SETTING, AND PARTICIPANTS Using Veterans Affairs andMedicare claims data, this
study examined hip and pelvic fracture hospitalizations in Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial participants randomized to first-step
therapy with a thiazide-type diuretic (chlorthalidone), a calcium channel blocker (amlodipine
besylate), or an angiotensin-converting enzyme inhibitor (lisinopril). Recruitment was from
February 1994 to January 1998; in-trial follow-up ended in March 2002. Themean follow-up
was 4.9 years. Posttrial follow-up was conducted through the end of 2006, using passive
surveillance via national databases. For this secondary analysis, which used an
intention-to-treat approach, data were analyzed from February 1, 1994, through December
31, 2006.
MAIN OUTCOMES ANDMEASURES Hip and pelvic fracture hospitalizations.
RESULTS A total of 22 180 participants (mean [SD] age, 70.4 [6.7] years; 43.0% female; and
49.9%white non-Hispanic, 31.2% African American, and 19.1% other ethnic groups) were
followed for up to 8 years (mean [SD], 4.9 [1.5] years) during masked therapy. After trial
completion, 16 622 participants for whom claims data were available were followed for up to
5 additional years (mean [SD] total follow-up, 7.8 [3.1] years). During the trial, 338 fractures
occurred. Participants randomized to receive chlorthalidone vs amlodipine or lisinopril had
a lower risk of fracture on adjusted analyses (hazards ratio [HR], 0.79; 95% CI, 0.63-0.98;
P = .04). Risk of fracture was significantly lower in participants randomized to receive
chlorthalidone vs lisinopril (HR, 0.75; 95% CI, 0.58-0.98; P = .04) but not significantly
different compared with those randomized to receive amlodipine (HR, 0.82; 95% CI,
0.63-1.08; P = .17). During the entire trial and posttrial period of follow-up, the cumulative
incidence of fractures was nonsignificantly lower in participants randomized to receive
chlorthalidone vs lisinopril or amlodipine (HR, 0.87; 95% CI, 0.74-1.03; P = .10) and vs each
medication separately. In sensitivity analyses, when 1 year after randomization was used as
the baseline (to allow for the effects of medications on bone to take effect), similar results
were obtained for in-trial and in-trial plus posttrial follow-up.
CONCLUSIONS AND RELEVANCE These findings from a large randomized clinical trial provide
evidence of a beneficial effect of thiazide-type diuretic therapy in reducing hip and pelvic
fracture risk compared with treatment with other antihypertensive medications.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00000542
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H
ypertension and osteoporotic fractures are age-
relateddisorderswhose incidences increase rapidlyaf-
ter the age of 65 years. The conditions are interre-
lated because people with hypertension have more
osteoporotic fractures thanpeoplewithouthypertension.1,2A
meta-analysis3 revealed thatmanynonrandomized, observa-
tional studies suggest that therapywith thiazide-type diuret-
ics improves bone strength and reduces fracture risk. A posi-
tive effect on calcium balance and a direct stimulatory effect
on osteoblasts have been proposed as the biological basis for
thisputativebeneficial effect.4β-Blockersmayalso reduce frac-
ture risk5 (possibly through β2-adrenergic blockade of recep-
tors present onosteoclasts6), althougha reviewarticle7 found
that not all studies confirm this. Less is known regarding the
effects of angiotensin-converting enzyme inhibitors (ACEis)
and calcium channel blockers (CCBs) on fracture risk despite
their ubiquitous use in older adults with hypertension.
Studies8,9 have found that ACEis exert a protective effect on
bone strength through blockade of local angiotensin produc-
tion,which stimulates osteoclast activity, and reductionof re-
ceptor activatornuclear factor–κβ ligand inosteoblasts,which
activatesosteoclasts.Several clinical studiessuggest lower frac-
ture riskwith their use,10,11 althoughnot all studies agree.12-15
Another study16 found that CCBs decrease bone resorption
through reduced osteoclast function owing to lower cytoso-
lic calcium.Little information is available regarding their clini-
cal effect on bone health.
The Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT) was a large randomized
clinical trial that compared theeffect of first-step therapywith
different classes of antihypertensive drug therapy inprevent-
ing fatal coronary heart disease (CHD) or nonfatalmyocardial
infarction (primary outcome) and other cardiovascular dis-
ease (CVD) events. The CCB amlodipine, the ACEi lisinopril,
and the α-receptor blocker doxazosin mesylate were not su-
perior to the diuretic chlorthalidone in preventing the pri-
mary CHD outcome or any other major CVD or renal
outcomes.17Chlorthalidonewas superior to amlodipine, lisin-
opril, and doxazosin in preventing heart failure and to lisino-
pril (blacksonly) anddoxazosin inpreventing stroke.The large
sample size, long follow-up, and randomized therapy pro-
vide a unique opportunity to examine post hoc the effects of
themajor classes of blood pressure–loweringmedications on
the incidence of hospitalizations for hip and pelvic fractures.
These fracture types are well captured in administrative data
sets and are serious fracture types that canbe associatedwith
mortality. We asked 3 questions: Are hip and pelvic fractures
less common during treatment with a thiazide-type diuretic
comparedwithCCBsorACEis?Does theadditionof aβ-blocker
to chlorthalidone further lower the risk of fracture? Assum-
ing a beneficial effect in the chlorthalidone group during the
trial, would this pattern continue during the posttrial period
(ie, is there a legacy effect)?
To answer these questions, we used 2 approaches. First,
we examined the cohort from the time of randomization
until the time of event (fracture) or censoring (death or end
of follow-up), thus maintaining the randomized allocation of
participants. Second, as a sensitivity analysis, we examined
the cohort beginning 1 year after the onset of the study.
Although randomization is not strictly maintained with this
approach, this was done for 2 reasons: to allow for the effect
of antihypertensive medications on bone to take place and
to avoid including early fractures associated with falls
related to use of new antihypertensive medications. Several
studies have reported increased risk of falls (a proximate
event in 90%-95% of hip fractures18) in new users of antihy-
pertensive medications.19,20 This study examines whether
the use of thiazide diuretics for the treatment of hyperten-
sion is associated with reduced fracture risk compared with
nonuse. We hypothesized fewer in-trial fracture hospitaliza-
tions in those randomized to chlorthalidone vs comparators
and that this benefit would persist into the posttrial surveil-
lance period when participants were no longer randomized
to study medications.
Methods
ALLHAT was a randomized, double-blind, active-controlled,
clinical hypertension trial that compared first-step treatment
with the thiazide-typediuretic chlorthalidone (n = 15255), the
CCB amlodipine (n = 9048), the α-receptor blocker doxazo-
sin (n = 9061), or the ACEi lisinopril (n = 9054).21 The doxa-
zosin arm was stopped early because of a higher risk of CVD
comparedwith chlorthalidone and is not consideredhere. All
participantsgavewritten informedconsent, andall centersob-
tained institutional reviewboardapproval for the trial. The in-
stitutional reviewboardofTheUniversity ofTexasHealth Sci-
enceCenteratHoustonapproved theposttrial follow-upstudy.
The authors outside the Coordinating Center did not have ac-
cess to participant-level identifying data.
Eligible participants forALLHATweremenandwomen55
years or older who had systolic blood pressure of at least 140
mm Hg and/or diastolic blood pressure of at least 90 mm Hg
or took medication for hypertension and had at least 1 addi-
tional risk factor for CHD. These risk factors included previ-
ousmyocardial infarction or stroke, left ventricular hypertro-
phy by electrocardiography or echocardiography, history of
Key Points
Question Do thiazide diuretics protect against fracture risk?
Findings Use of the thiazide-like diuretic chlorthalidone was
associated with a 21% significantly lower risk of hip and pelvic
fractures compared with either lisinopril or amlodipine and a
significantly lower risk compared with lisinopril alone during
approximately 4.9 years of follow-up. During 5 additional years of
posttrial follow-up, whenmedication use was not constrained by
study protocol, fracture risk continued to be lower in users of
chlorthalidone compared with lisinopril or amlodipine together
or alone.
Meaning The present results of short-term and long-term fracture
protection with thiazide antihypertensive therapy compared with
other antihypertensive medications strongly recommend use of
a thiazide for hypertension treatment in addition to its long track
record of cardiovascular protection.
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type 2 diabetes, current cigarette smoking, and low high-
density lipoprotein cholesterol level. Exclusion criteria in-
cludedmyocardial infarction, stroke, or anginapectoriswithin
6 months of study entry; symptomatic heart failure or ejec-
tion fraction less than 35%; creatinine level greater than
2mg/dL (to convert tomicromoles per liter,multiply by88.4);




The step 1 studymedications (chlorthalidone, 12.5-25mg; am-
lodipine, 2.5-10 mg; and lisinopril, 10-40 mg) were formu-
lated to lookalike so that the identityofeachagentwasdouble-
masked. The doses were titrated to achieve a blood pressure
lower than 140/90 mm Hg. If goal blood pressure was not
achieved using themaximum tolerated dose, open-label step
2 (reserpine, clonidine, or atenolol) or step 3 (hydralazine)
medications could be added.
Recruitment and Follow-up
Recruitment was from February 1, 1994, through January 31,
1998; in-trial follow-up endedMarch 31, 2002. Themean (SD)
follow-up was 4.9 (1.5) years. Posttrial follow-up was con-
ducted through theendof2006,usingpassive surveillancevia
national databases.22
Hip and Pelvic Fracture Cohorts
Fracture datawere ascertained through the Centers forMedi-
care & Medicaid Services and Veterans Affairs (VA) hospital-
izationdata fromFebruary1, 1994, throughDecember31,2006,
for beneficiaries with valid Medicare or Social Security iden-
tifiers.Participantsyounger than65yearsat randomizationen-
rolledbynon-VAclinicsandparticipants fromCanadawerenot
included because they would not have had continuous cov-
erage in either data source. The VA data files were not avail-
able for the posttrial follow-up (2002-2006); therefore, the
posttrial cohort was limited to US citizenswithMedicare Part
A insurance at randomization (Figure 1). Hospitalizedhip and
pelvic fractures (International Classification ofDiseases,Ninth
Revision, codes820.x and808.x, respectively)were chosenas
endpointsbecause theyarealmostalwaysassociatedwithhos-
pitalization. Such ascertainment results in less underestima-
tion of hip fracture incidence than methods based on
self-report.23Foreachparticipant, the time to first fracturewas
calculated for the maximal period of follow-up from base-
line. For sensitivity analyses, the incidence of fractures was
calculated beginning 1 year after study enrollment.
Statistical Analysis
Data are summarized asmeans (SDs) for continuous variables
andnumbers (percentages) of studyparticipants for categori-
cal variables. Baseline characteristics were compared across
the treatment groups using 2-tailed, unpaired t tests for con-
tinuous variables and χ2 contingency table analyses for cat-
egorical variables.
Atenolol usewasnot ascertainedat baseline. Becausepar-
ticipantswhowere already taking atenolol at baselinewere al-
lowed to continue to take atenolol and atenolol was a step 2
drug, participants taking atenolol at the first follow-up visit
(1 month) were assumed to be taking atenolol at baseline.
The estimated glomerular filtration rate (eGFR)wasmea-
suredusing theModificationofDiet inRenalDiseaseStudyand
the Chronic Kidney Disease Epidemiology Collaboration
equations.24 Both estimations were used because outcomes
vary, and we wished to capture any possible diminished re-
nal function (eGFR <60mL/min/1.73 m2).
Outcomes analysis used an intention-to-treat approach.
Fracture rates andgraphsused theKaplan-Meiermethod.The
Cox proportional hazards regression model was used to de-
terminehazard ratios (HRs) and95%CIs. Individualswerecen-
sored for outcomes if they died, had no outcome in the data-
base by the end of the study, or were lost to follow-up.
Proportional hazards were tested by including a time × treat-
mentvariable in theCoxproportionalhazards regressionmod-
els and found to hold. Adjusted Cox proportional hazards re-
gression models included age, race, sex, diabetes, eGFR,
prevalent CVD, body mass index, and smoking. For the pri-
mary analyses,we combined those separately assigned to am-
lodipineand lisinopril into 1group forgreater statistical power.
Separate comparisonsof amlodipineand lisinopril to chlortha-
lidone were conducted as secondary analyses.
Heterogeneity of treatment effects on outcomes was ex-
aminedusing treatment-variable interaction terms inCoxpro-
Figure 1. CONSORTDiagrams
15 255 Received chlorthalidone
as randomized
18 102 Received amlodipine or
lisinopril as randomized
33 357 Participants randomized
10 174 CMS or VA cohorts
398 Taking atenolol at 1 mo
9776 Not taking atenolol at
1 mo
12 006 CMS or VA cohorts
452 Taking atenolol at 1 mo
11 554 Not taking atenolol at
1 mo
In-trial cohortA
15 255 Received chlorthalidone
as randomized
18 102 Received amlodipine or
lisinopril as randomized
33 357 Participants randomized
7631 CMS 
280 Taking atenolol at 1 mo
7351 Not taking atenolol at
1 mo
8991 CMS
300 Taking atenolol at 1 mo
8691 Not taking atenolol at
1 mo
In-trial plus posttrial cohortB
Atenolol status at 1 month for the in-trial (A) and in-trial plus posttrial (B) cohorts. CMS indicates Centers for Medicare &Medicaid Services; VA, Veterans Affairs.
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portional hazards regression models, with P < .05 indicating
statistical significance. Heterogeneity was assessed for age,
race, sex, diabetes, eGFR, incident and prevalent CVD, body
mass index, smoking, and (for females) hormone replace-
ment therapy.Given themanysubgroupand interactionanaly-
sesperformed,statistical significanceat theP < .05 level should
be interpreted with caution. All statistical analyses were per-
formed using STATA software, version 13 or 14 (StataCorp).
Results
A total of 22 180 participants (mean [SD] age, 70.4 [6.7]
years; 43.0% female; and 49.9% white non-Hispanic, 31.2%
African American, and 19.1% other ethnic groups) were fol-
lowed up for as long as 8 years (mean [SD], 4.9 [1.5] years)
during masked therapy. After trial completion, 16 622 par-
ticipants for whom claims data were available were followed
up for as long as 5 additional years (mean [SD] total follow-
up, 7.8 [3.1] years). The in-trial cohort consisted of partici-
pants randomized to chlorthalidone, amlodipine, or lisino-
pril, with or without atenolol at month 1 of follow-up from
baseline (Figure 1A). Of 33 357 participants, 22 180 (66.5%)
were in the Medicare or the VA system databases. Details of
the cohort (n = 16 622) with in-trial and posttrial follow-up
are shown in Figure 1B. Baseline characteristics of the 2
cohorts are given in eTable 1 and eTable 2 in the Supple-
ment. The groups were equally balanced in all aspects
except that in-trial participants randomized to receive
chlorthalidone had more baseline CHD than the amlodipine
and lisinopril groups (29.3% vs 27.8%, P < .05). Figure 2
shows the cumulative fracture rates for both cohorts.
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8766 8124 7703 7054 6398 5783 5176 4337 24328467
7443 6914 6529 5997 5441 4894 4405 3694 20887204
Initial curves for the in-trial (A) and in-trial plus posttrial (B) cohorts and curves
from year 1 onward after randomization for the in-trial (C) and in-trial plus
posttrial (D) cohorts. For the initial curves (A and B), in the in-trial cohort, the
unadjusted hazard ratio (HR) was 0.79 (95% CI, 0.63-0.97) and the adjusted HR
was 0.79 (95% CI, 0.63-0.98) for chlorthalidone vs amlodipine or lisinopril; in
the in-trial plus posttrial cohorts, the unadjusted HRwas 0.87 (95% CI,
0.74-1.02) and the adjusted HRwas 0.87 (95% CI, 0.74-1.03) for chlorthalidone
vs amlodipine or lisinopril. For the curves from year 1 onward after
randomization (C and D), in the in-trial cohort, the unadjusted hazard ratio (HR)
was 0.78 (95% CI, 0.62-0.98) and the adjusted HRwas 0.77 (95% CI,
0.60-0.98) for chlorthalidone vs amlodipine or lisinopril; in the in-trial plus
posttrial cohorts, the unadjusted HRwas 0.88 (95% CI, 0.75-1.03) and the
adjusted HRwas 0.87 (95% CI, 0.73-1.03) for chlorthalidone vs amlodipine
or lisinopril.
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In-Trial Cohort
Thirty-four participants had pelvic fractures and 307 partici-
pants had hip fractures during the in-trial period (mean [SD]
follow-up, 4.9 [1.5] years). Threeof these individuals hadboth
hipandpelvic fractures.Cumulative fracture rates andHRsare
given in theTable andFigure 2A. Inunadjusted analyses, par-
ticipants randomized to receive chlorthalidone had signifi-
cantly decreased risk (HR, 0.78; 95%CI, 0.63-0.97;P = .03) of
fractures compared with those randomized to receive lisino-
pril or amlodipine. The increased risk appeared by the sec-
ond year after randomization for those taking amlodipine or
lisinopril. Similar resultswerenotedafteradjustment fordemo-
graphic and clinical variables (HR, 0.79; 95% CI, 0.63-0.98;
P = .04). Similar trends were found when chlorthalidone use
was compared with lisinopril or amlodipine use separately
(eFigure 1 in the Supplement). Chlorthalidone use was asso-
ciatedwitha significantly lower riskof fracture comparedwith
lisinopril use (HR, 0.75; 95% CI, 0.58-0.98; P = .04), whereas
the risk with amlodipine use was not statistically significant
(HR, 0.82; 95% CI, 0.63-1.08; P = .15).
Thepotential effect of atenolol use on fracture risk in par-
ticipants takingchlorthalidoneduring the in-trial period ispre-
sented in eTable 3 and eFigure 2 in the Supplement. No sig-
nificant difference was found between those taking or not
taking atenolol. TheunadjustedHR for atenolol userswas 1.43
(95% CI, 0.67-3.07). Adjustment for demographic and clini-
cal variablesmarginally changed this estimate (HR, 1.29; 95%
CI, 0.56-2.95).
Fully adjustedhipandpelvic fractureHRs, stratifiedbyse-
lected variables, are shown for the in-trial cohort in Figure 3
and eFigure 3 in the Supplement. In all instances, use of
chlorthalidone was associated with a lower risk of fracture
than amlodipine or lisinopril. In several instances, the use of
chlorthalidone was associated with a significantly lower risk
(eGFR ≥60 mL/min/1.73 m2 using the Modification of Diet in
Renal Disease formula, age ≥65 years, race other than black,
and overweight). Interaction terms were not statistically sig-
nificant (with P values ranging from .16 to .99). Similar find-
ings were present when lisinopril or amlodipine use vs
chlorthalidoneusewas examined separately (eFigure 3 in the
Supplement), with a higher fracture risk in more subgroups
treated with lisinopril (Modification of Diet in Renal Disease
eGFR >60mL/min/1.73m2, prevalent CVD, male sex, age >65
years, raceother thanblack) comparedwithamlodipine (over-
weight).
CohortWith In-Trial and Posttrial Follow-up
Seventypelvicand576hipfracturesoccurred inthecohortwith
in-trial and posttrial follow-up. Cumulative fracture rates are
shown inFigure 2B. The fracture rateswere somewhat higher
Table. Mean (SD) Hip or Pelvic Fracture Rates per 100 Person-years FromBaseline Onward
During the In-Trial Perioda
Rate
Chlorthalidone
(n = 10 174)
Amlodipine or Lisinopril
(n = 12 006)
Total
(N = 22 180)
No. of hip or pelvic fractures 135 203 338
Unadjusted rate
Year 1 0.19 (0.04) 0.23 (0.04) 0.21 (0.03)
Year 2 0.47 (0.07) 0.51 (0.07) 0.50 (0.05)
Year 3 0.68 (0.08) 0.87 (0.09) 0.78 (0.06)
Year 4 1.02 (0.10) 1.18 (0.10) 1.11 (0.07)
Year 5 1.33 (0.12) 1.65 (0.13) 1.50 (0.09)
Age-adjusted rate
Year 1 0.12 (0.03) 0.17 (0.03) 0.15 (0.02)
Year 2 0.30 (0.04) 0.39 (0.05) 0.35 (0.03)
Year 3 0.44 (0.05) 0.67 (0.07) 0.56 (0.04)
Year 4 0.68 (0.07) 0.92 (0.08) 0.81 (0.05)
Year 5 0.90 (0.08) 1.30 (0.10) 1.11 (0.07)
Age- and sex-adjusted rate
Year 1 0.12 (0.03) 0.17 (0.03) 0.14 (0.02)
Year 2 0.30 (0.04) 0.38 (0.05) 0.34 (0.03)
Year 3 0.43 (0.05) 0.64 (0.06) 0.54 (0.04)
Year 4 0.66 (0.07) 0.88 (0.08) 0.78 (0.05)
Year 5 0.88 (0.08) 1.24 (0.09) 1.07 (0.06)
Age-, sex-, and race-adjusted rate
Year 1 0.11 (0.03) 0.16 (0.03) 0.13 (0.02)
Year 2 0.28 (0.04) 0.35 (0.05) 0.32 (0.03)
Year 3 0.40 (0.05) 0.60 (0.06) 0.51 (0.04)
Year 4 0.62 (0.06) 0.83 (0.07) 0.73 (0.05)
Year 5 0.82 (0.08) 1.17 (0.09) 1.01 (0.06)
a The hazard ratios (95% CIs) for
taking chlorthalidone vs not taking
chlorthalidone are as follows:
unadjusted rate, 0.78 (0.63-0.97);
age-adjusted rate, 0.79 (0.63-0.98);
age- and sex-adjusted rate, 0.78
(0.63-0.97); and age-, sex-, and
race-adjusted rate, 0.78
(0.63-0.97).
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than in the in-trial cohort, likely because of the older age of
the cohort with extended follow-up. No significant differ-
encewas found in the riskof fracturesbetween those random-
ized to receive chlorthalidone vs those randomized to receive
amlodipine or lisinopril (unadjusted HR, 0.87; 95% CI, 0.74-
1.02;P = .09; adjustedHR,0.87; 95%CI,0.74-1.03;P = .10), al-
though users of chlorthalidone had persistently nonsignifi-
cantly lower risk after year 3 of follow-up.When fracture risk
was examined by amlodipine or lisinopril use vs chlorthali-
done use separately (eFigure 1 in the Supplement), no signifi-
cant differences were found between use of lisinopril or am-
lodipinevs chlorthalidoneuse (chlorthalidonevs amlodipine:
unadjusted HR, 0.85; 95% CI, 0.70-1.02; P = .08; ad-
justed HR, 0.87; 95% CI, 0.71-1.09; P = .16; chlorthalidone vs
lisinopril: unadjusted HR,0.90;95%CI,0.75-1.08;P = .28; ad-
justed HR,0.87; 95%CI,0.71-1.09;P = .17), althoughchlortha-
lidone use was associated with a lower risk of fracture.
Sensitivity Analyses
Analyseswere repeated beginning 1 year after randomization
to gauge the effects of the medications on fracture risk after
trial participants had been exposed to the bone effects of the
medications for 1 year. In the in-trial cohort, 21 721 (65%)of the
33357participants in theMedicareorVAsystemdatabases sur-
vived 1 year after randomization. There were 16 263 with in-
trial and posttrial follow-up.
During the in-trial period (mean [SD] follow-up, 3.8 [1.6]
years), 32 participants had a pelvic fracture and 266 had a hip
fracture. In the cohortwith in-trial andposttrial follow-up, 69
pelvic and 545 hip fractures occurred during the in-trial and
posttrial periods. The in-trial and the in-trial plus posttrial re-
sults 1 year after randomization (Figure 2C and D) were simi-
lar to the in-trial and in-trial plusposttrial results fromthe time
of randomization (Figure 2A and B).
Discussion
This post hoc analysis of an older cohort randomly assigned
to3classesof first-stepantihypertensivemedicationhas2main
findings. First, the risk of hip and pelvic fractures during in-
trial follow-up was lowest in participants assigned to first-
step therapy with chlorthalidone compared with amlodipine
or lisinopril. This findingwas consistent in all subgroup com-
parisons. Similar results were obtained in sensitivity analy-
ses,where the first year of follow-up after randomizationwas
excluded. To our knowledge, this analysis provides the first
randomized comparison of different antihypertensive medi-
cations on risk of hip or pelvic fractures. Consistent with our
findings, ameta-analysis3 of 21 case-control and cohort stud-
ies concluded that treatment with thiazide diuretics was as-
sociated with a 24% lower risk of hip fracture comparedwith
other antihypertensive agents (HR, 0.76; 95% CI, 0.64-0.89).
Second, analyses that included in-trial and posttrial fol-
low-up yielded a fracture risk thatwas no longer significantly
different between the treatment groups, albeit it was still nu-
merically lowest in the chlorthalidone group. Our analyses
based onposttrial and in-trial experiencewere not based on a
Figure 3. Adjusted In-Trial Hazard Ratios for Hip or Pelvic Fracture in Those Randomized to Receive






Hip or Pelvic Fracture, HR (95% CI)
Demographic Characteristic HR (95% CI)
Total 0.79 (0.63-0.98)
No DM 0.83 (0.62-1.10)
DM 0.73 (0.51-1.06)
Baseline MDRD eGFR ≥60 mL/min/1.73 m2 0.73 (0.55-0.97)
Baseline MDRD eGFR <60 mL/min/1.73 m2 0.89 (0.61-1.29)
Baseline CKD eGFR ≥60 mL/min/1.73 m2 0.76 (0.57-1.02)
Baseline CKD eGFR <60 mL/min/1.73 m2 0.82 (0.58-1.16)
No CVD 0.83 (0.57-1.20)
Prevalent CVD 0.76 (0.58-1.01)
Male 0.82 (0.57-1.18)
Female 0.77 (0.57-1.02)
Age <65 y 0.70 (0.23-2.15)
Age ≥65 y 0.78 (0.62-0.98)
Black 0.85 (0.53-1.37)
Non-black 0.76 (0.59-0.99)
Healthy weight 0.89 (0.65-1.23)
Overweight 0.60 (0.39-0.91)
Obese 0.83 (0.49-1.40)
Current smoker 0.83 (0.50-1.37)
Former smoker 0.80 (0.54-1.17)
Never smoked 0.79 (0.56-1.10)
Estrogen 0.69 (0.25-1.88)
No estrogen 0.78 (0.57-1.05)
Hazards ratios (HRs) were adjusted
for age, race, sex, diabetes, baseline
estimated glomerular filtration rate
(eGFR), prevalent cardiovascular
disease (CVD), bodymass index, and
smoking. For estrogen, analyses are
for women only. CKD indicates
chronic kidney disease; DM, diabetes
mellitus; andMDRD, Modification of
Diet in Renal Disease.
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randomized comparison and thus are subject to bias. More-
over, during the posttrial period, the choice of blood pressure
medication was no longer constrained by the study protocol;
therefore, those originally randomized to receive chlorthali-
done might have stopped using this medication and non-
chlorthalidone users might have begun to take a thiazide di-
uretic. A population study25 found that thiazide diuretic
use increased in the United States after publication of the
ALLHAT results. Despite these caveats, participants random-
ized to receive chlorthalidoneduring the in-trial periodcontin-
ued to have a lower point estimate of fracture risk 5 years after
study completion, suggesting (but not proving) a legacy ef-
fect.Suchafinding isatoddswith2otherstudies.18,26 Inastudy
of healthy women early in menopause,26 use of a thiazide di-
uretic for 2yearsprevented lossofbonemineraldensity (BMD)
in the forearmcomparedwithplacebo.Oneyear after the thia-
zide use was stopped, there was no difference in BMD com-
paredwith theplacebogroup, suggesting rapid loss of theben-
eficialeffectof thediuretic.TheRotterdamstudy18 reportedthat
the presumedhip fracture protective effect of thiazides disap-
peared 4months after discontinuation of diuretic therapy.
When we examined the in-trial fracture risk in users of
lisinopril and amlodipine separately, we found a significantly
higher risk in those randomizedto receive lisinopril butnotam-
lodipinecomparedwithchlorthalidone.This findingcontradicts
thepositiveeffectsthatACEisarebelievedtoexertonbonephysi-
ologic mechanisms10 but is consistent with several clinical
studies.12-15,27A4-year observational study27 fromHongKong
foundthat continuoususeofACEis comparedwithnonusewas
associatedwithgreaterBMDlossinthetotalhipandfemoralneck
in women. In a prospective cohort study12 of 5995 older men
fromtheOsteoporoticFractures inMenStudy,with4.6yearsof
follow-up, continuoususeofACEis comparedwithnonusewas
associatedwith a small but significantly higher loss of BMD in
the trochanter and total hip. IncreasedBMD losswithACEiuse
vsnonusewasnoted ina Japanese cohort.13 In a studyofMedi-
caredata,14 thenumberofhip fractureswas approximately 14%
higher in users of ACEis compared with thiazide diuretics, al-
though theHRwas not statistically significant. In the Study of
Women’sHealthAcrosstheNation,15 thiazideusewasassociated
withlessannualizedBMDlosscomparedwithnonusersandcom-
pared with ACEis and β-blockers. Given these results and the
widespread use of ACEis for the treatment of hypertension in
olderadults,our findinghaspotentially importantpublichealth
implications.However, ahigher riskof fractureor lowerBMDin
ACEiusershasnotbeenauniversal finding,andsomestudies10,11
report a protective effect of renin angiotensin blockade.
Inour study, theβ-blockeratenololdidnot seemtoact syn-
ergistically with chlorthalidone to yield a lower fracture risk.
In fact, use of atenolol together with chlorthalidone was as-
sociatedwithanonsignificantly increased riskof fracturecom-
paredwithuseof chlorthalidonealone.Given thatatenololwas
used as an add-onmedication inALLHAT, this finding should
be viewed with a great deal of caution.
This study has important strengths. We were able to ex-
aminetreatmenteffects foranextendedperiod.Ourcohortwas
large and well characterized, allowing adjustment for vari-
ables that affect bone health. Our sample was based on par-
ticipantswhohadbeen randomized to their treatment group,
minimizing differences between the treatment groups.
Limitations
Studyweaknesses should also be acknowledged. First, analy-
ses, although performed in a randomized setting, were con-
ducted post hoc, and results are subject to unmeasured bias.
Second, participation inALLHATexcluded several groups
of participants at high risk for fracture, such as thosewith ac-
tive coronary artery disease andheart failure10,28 and chronic
kidney disease.29Our results cannot be extrapolated to these
groups. In addition, as inmany large trials, only variables that
were important to the primary goal of the study were col-
lected; thus, we lacked covariates such as menstrual history
(women), testosterone levels (men), history of falls (a proxi-
mate event inmosthip andpelvic fractures), andbisphospho-
nate use. We note that alendronate, the first approved
bisphosphonate, was approved by the US Food and Drug Ad-
ministration in late 1995, approximately 18 months after the
onset of ALLHAT. It would have become available in themar-
ket 6months later at the earliest. Therefore, bisphosphonate
use would not have influenced the early in-trial results of
ALLHAT.Moreover, theuse of bisphosphonates becamecom-
mon only in the early 2000s, after the release of several large
fracture trials.30 Thus, it is unlikely that the in-trial fracture
ratewas strongly influenced by the use of these agents. In ad-
dition, it is unlikely that bisphosphonate use would differ by
randomized treatment arm.
Third, we relied on databases (rather than medical rec-
ords) to ascertain fracture occurrence. Although this ap-
proach is highly accurate for diagnosing fractures,23 partici-
pants eligible forMedicarewhowereenrolled inmanagedcare
would not have hospitalizations recorded with Medicare,
thereby lowering the number of participants with fractures.
In ALLHAT, approximately 20% of Medicare eligible patients
were inmanagedcare at somepointduring follow-upand thus
were not eligible to have hospitalization records in the data-
base; 8% (40% of participants withmanaged care indicators)
didnot have such indicators in theCMSdatabaseuntil the last
2 years of posttrial follow-up (2005 and 2006).
Fourth, although randomizationwas generallywellmain-
tained during the trial period, therewas crossover ofmedica-
tion use.17 Among all participants, 80.5% of the chlorthali-
done, 80.4% of the amlodipine, and 72.6% of the lisinopril
groups were taking their assigned medications (or one in an
equivalent class) at their 5-year follow-upvisit. Amongall par-
ticipants, 9.0%of the chlorthalidone groupwere taking aCCB
or an ACEi without a diuretic at 5 years; 23.5% of the amlo-
dipine group and 24.2% of the lisinopril group were taking a
diuretic with or without their assigned study medications at
5 years. Such crossoverwould tend to decrease differences in
fracture outcomes betweenmedication classes.
Conclusions
This secondary analysis of a randomized clinical trial con-
firms previous observational reports that use of thiazide-
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typediuretics is associatedwith significantly lower risk of hip
and pelvic fractures compared with treatment with an ACEi
oraCCB.Thiseffect is consistentlyobserved inavarietyof sub-
groups and appears to last for several years.
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eTable 1. Baseline Characteristics for the In-Trial Cohort 
 Chlorthalidone Amlodipine/Lisinopril Total
N 10174 12006 22180
Age – mean (sd) years 70.4 (6.7) 70.4 (6.8) 70.4 (6.7)
55-64 – n (%) 1531 (15.1) 1798 (15.0) 3329 (15.0)
65+ - n (%) 8643 (85.0) 10208 (85.0) 18851 (85.0)
Female – n (%) 4413 (43.4) 5118 (42.6) 9531 (43.0)
Ethnicity    
White non-Hispanic – n (%) 5072 (49.9) 5996 (49.9) 11068 (49.9)
Black non-Hispanic – n (%) 3169 (31.2) 3742 (31.2) 6911 (31.2)
White Hispanic – n (%) 1204 (11.8) 1432 (11.9) 2636 (11.9)
Black Hispanic – n (%) 311 (3.1) 371 (3.1) 682 (3.1)
Other n (%) 418 (4.1) 465 (3.9) 883 (4.0)
Education, mean (sd) years 10.7 (4.1) 10.7 (4.1) 10.7 (4.1)
Receiving antihypertensive treatment – 
n (%) 
9264 (91.1) 10969 (91.4) 20233 (91.2)
Blood pressure – mean (sd) mm Hg    
SBP 146.6 (15.8) 146.6 (15.6) 146.6 (15.7)
DBP 82.8 (10.1) 82.7 (10.1) 82.8 (10.1)
Treated at baseline    
SBP 145.6 (15.8) 145.6 (15.6) 145.6 (15.7)
DBP 82.3 (10.1) 82.3 (10.0) 82.3 (10.0)
Untreated at baseline    
SBP 156.6 (11.6) 157.1 (11.7) 156.9 (11.7)
DBP 87.8 (9.0) 87.6 (9.5) 87.7 (9.3)
Eligibility risk factors—n (%):    
Current smoking  1915 (18.8) 2229 (18.6) 4144 (18.7)
Atherosclerotic CVD  5756 (56.6) 6673 (55.6) 12429 (56.0)
History of MI or stroke  2744 (27.0) 3125 (26.0) 5869 (26.5)
History of coronary revascularization  1510 (14.8) 1746 (14.5) 3256 (14.7)
Other ASCVD  2611 (25.7) 3083 (25.7) 5694 (25.7)
Major ST depression or T-wave 
inversion  
1064 (10.6) 1247 (10.5) 2311 (10.5)
Diabetes † 4011 (42.5) 4785 (42.9) 8796 (42.7)
HDL-C < 35 mg/dL  1232 (12.1) 1462 (12.2) 2694 (12.2)
LVH by electrocardiogram  1702 (16.7) 2027 (16.9) 3729 (16.8)
LVH by echocardiogram  500 (5.0) 587 (5.0) 1087 (5.0)
History of CHD at baseline  2959 (29.3) 3305 (27.8)* 6264 (28.5)
Body mass index – mean (sd) 29.1 (5.8) 29.1 (5.8) 29.1 (5.8)
Medication use at baseline – n (%)    
Aspirin  3904 (38.4) 4704 (39.2) 8608 (38.8)
Estrogen supplementation– 
FEMALES ONLY 
614 (13.9) 684 (13.4) 1298 (13.6)
Atenolol use at 1 month  398 (3.9) 452 (3.8) 850 (3.8) 
Cholesterol– mean (sd, N)    






HDL  46.7 (14.7, 9699) 46.8 (14.7, 11386) 46.7  
(14.7, 21085)
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Serum creatinine – mean (sd, N) 1.1 (0.3, 9751) 1.0 (0.3. 11446) 1.1 (0.3, 21197)
eGFR--– mean (sd, N)    
Baseline --MDRD  74.9 (19.5, 9751) 75.3 (19.4, 11446) 75.1 (19.4, 
21197)
Baseline – CKD-Epi  70.7 (17.6, 9751) 71.0 (17.5, 11446) 70.8 (17.6, 
21197)
Lipid trial participants – n (%) 2423 (23.8) 2783 (23.2) 5206 (23.5)
Abbreviations: ASCVD, arteriosclerotic cardiovascular disease; CCVD, combined cardiovascular disease; 
CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; 
MDRD, modification of diet in renal disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; 
LVH, left ventricular hypertrophy; MI, myocardial infarction 
*p < 0.05  
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eTable 2. Baseline Characteristics for the In-Trial Plus Posttrial Cohort  
 Chlorthalidone Amlodipine/Lisinopril Total 
N 7631 8991 16622 
Age – mean (sd) years 71.3 (6.6) 71.4 (6.6) 71.4 (6.6) 
55-64 – n (%) 656 (8.6) 782 (8.7) 1438 (8.7) 
65+ - n (%) 6975 (91.4) 8209 (91.3) 15184 (91.4) 
Female – n (%) 4362 (57.2) 5053 (56.2) 9415 (56.6) 
Ethnicity    
White non-Hispanic – n (%) 3483 (45.6) 4069 (45.3) 7552 (45.4) 
Black non-Hispanic – n (%) 2401 (31.5) 2837 (31.6) 5238 (31.5) 
White Hispanic – n (%) 1108 (14.5) 1340 (14.9) 2448 (14.7) 
Black Hispanic – n (%) 285 (3.7) 331 (3.7) 616 (3.7) 
Other n (%) 354 (4.6) 414 (4.6) 768 (4.6) 
Education, mean (sd) years 10.4 (4.2) 10.4 (4.3) 10.4 (4.2) 
Receiving antihypertensive treatment – 
n (%) 
6903 (90.5) 8194 (91.1) 15097 (90.8) 
Blood pressure – mean (sd) mm Hg    
SBP 147.4 (15.6) 147.4 (15.5) 147.4 (15.5) 
DBP 83.2 (10.1) 83.0 (10.1) 83.1 (10.1) 
Treated at baseline    
SBP 146.4 (15.6) 146.4 (15.5) 146.4 (15.5) 
DBP 82.7 (10.0) 82.5 (10.0) 82.6 (10.0) 
Untreated at baseline    
SBP 157.0 (12.0) 157.6 (11.7) 157.3 (11.9) 
DBP 88.1 (8.9) 88.0 (9.3) 88.1 (9.1) 
Eligibility risk factors– n (%)    
Current smoking  1282 (16.8) 1493 (16.6) 2775 (16.7) 
Atherosclerotic CVD  4339 (56.9) 5010 (55.7) 9349 (56.2) 
History of MI or stroke  1923 (25.2) 2196 (24.4) 4119 (24.8) 
History of coronary revascularization  1082 (14.2) 1230 (13.7) 2312 (13.9) 
Other ASCVD  2086 (27.3) 2456 (27.3) 4542 (27.3) 
Major ST depression or T-wave 
inversion  
807 (10.7) 934 (10.5) 1741 (10.6) 
Diabetes† 3031 (43.1) 3604 (43.5) 6635 (43.3) 
HDL-C < 35 mg/dL  776 (10.2) 954 (10.6) 1730 (10.4) 
LVH by electrocardiogram  1254 (16.4) 1458 (16.2) 2712 (16.3) 
LVH by echocardiogram  414 (5.5) 499 (5.6) 913 (5.5) 
History of CHD at baseline  2099 (27.7) 2383 (26.7) 4482 (27.1) 
Body mass index – mean (sd) 29.1 (6.0) 29.2 (6.1) 29.2 (6.1) 
Medication use at baseline – n (%)    
Aspirin  2683 (35.2) 3208 (35.7) 5891 (35.4) 
Estrogen supplementation– 
FEMALES ONLY 
597 (13.7) 661 (13.1) 1258 (13.4) 
Atenolol use at 1 month 280 (3.7) 300 (3.3) 580 (3.5) 
Cholesterol– mean (sd, N)    
Total  217.5  
(44.1, 7239) 
216.6 (43.6, 8480) 217.0  
(43.9, 15719) 
HDL  48.2 (15.0, 7238) 48.2 (14.9, 8476) 48.2  
(14.9, 15714) 
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LDL  136.6  
(37.5, 6865) 
135.9 (36.9, 8051) 136.2  
(37.2, 14916) 
Serum creatinine – mean (sd, N) 1.0 (0.3, 7275) 1.0 (0.3, 8519) 1.0 (0.3. 15794) 
eGFR– mean (sd, N)    
Baseline– MDRD  73.9 (19.8, 7275) 74.1 (19.5, 8519) 74.0 (19.6, 
15794) 
Baseline – CKD-Epi  69.7 (17.8, 7275) 69.8 (17.7, 8519) 69.8 (17.7, 
15794) 
Lipid trial participants – n (%) 1847 (24.2) 2092 (23.3) 3939 (23.7) 
Abbreviations: ASCVD, arteriosclerotic cardiovascular disease; CCVD, combined cardiovascular disease; 
CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; 
MDRD, modification of diet in renal disease; HDL high-density lipoprotein; LDL, low-density lipoprotein; 
LVH, left ventricular hypertrophy; MI, myocardial infarction 
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eTable 3. Hip or Pelvis Fracture Rates per 100 and Hazard Ratios From Baseline Onward During 
the In-Trial Period for Chlorthalidone Only With or Without Atenolol Use at 1 Month  
 Total Not on Atenolol 
at 1 month 
On Atenolol at 1 
month 
N (denominator) 10174 9776 398 
Hip or pelvic fractures    
Events 135 128 7 
1-y rate 0.19 (0.04) 0.20 (0.05) 0.00 ( - ) 
2-y rate 0.47 (0.07) 0.45 (0.07) 1.04 (0.52) 
3-y rate 0.68 (0.08) 0.66 (0.08) 1.04 (0.52) 
4-y rate 1.02 (0.10) 0.98 (0.10) 1.91 (0.72) 
5-y rate 1.33 (0.12) 1.30 (0.12) 1.91 (0.72) 
HR on atenolol vs not on 
atenolol at 1 month (95% 
CI) 
1.43 (0.67-3.07)   
Age-Adjusted    
1-y rate 0.12 (0.03) 0.12 (0.03) 0.00 ( - ) 
2-y rate 0.30 (0.04) 0.28 (0.04) 0.90 (0.45) 
3-y rate 0.44 (0.05) 0.42 (0.05) 0.90 (0.45) 
4-y rate 0.67 (0.07) 0.64 (0.07) 1.66 (0.63) 
5-y rate 0.89 (0.08) 0.86 (0.08) 1.66 (0.63) 
HR on atenolol vs not on 
atenolol at 1 month (95% 
CI) 
1.67 (0.78-3.58)   
Age and sex-adjusted    
1-y rate 0.12 (0.03) 0.12 (0.03) 0.00 ( - ) 
2-y rate 0.30 (0.04) 0.28 (0.04) 0.89 (0.44) 
3-y rate 0.43 (0.05) 0.41 (0.05) 0.89 (0.44) 
4-y rate 0.66 (0.07) 0.63 (0.07) 1.65 (0.62) 
5-y rate 0.88 (0.08) 0.85 (0.08) 1.65 (0.62) 
HR on atenolol vs not on 
atenolol at 1 month (95% 
CI) 
1.66 (0.77-3.55)   
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Age, sex, and race-adjusted    
1-y rate 0.11 (0.03) 0.11 (0.03) 0.00 ( - ) 
2-y rate 0.28 (0.04) 0.26 (0.04) 0.88 (0.44) 
3-y rate 0.40 (0.05) 0.39 (0.05) 0.88 (0.44) 
4-y rate 0.62 (0.06) 0.59 (0.06) 1.61 (0.61) 
5-y rate 0.82 (0.08) 0.80 (0.08) 1.61 (0.61) 
HR on atenolol vs not on 
atenolol at 1 month (95% 
CI) 
1.50 (0.70-3.22)   
  
 
© 2016 American Medical Association. All rights reserved. 
 
 
eFigure 1. Kaplan-Meier Curves for Hip and Pelvic Fractures by the Three Primary Antihypertensive 
Medications Used in ALLHAT. Curves A and B are from the time of randomization during the in-trial and 
during the in-trial and posttrial periods. Curves C and D are from one year after randomization for the in-trial 
and the in-trial and posttrial periods. 
 
A. In-trial cohort              B. In-trial plus post-trial cohort 
 
 
 Hazard Ratio (95% CI), P Hazard Ratio (95% CI), P
Unadjusted A/C = 1.27 (0.98 – 1.64), P = 0.071 
L/C = 1.28 (0.99 – 1.66), P = 0.058 
A/C = 1.18 (0.98 – 1.42), P = 0.078 
L/C = 1.11 (0.92 – 1.34), P = 0.279 
Adjusted* A/C = 1.22 (0.93 – 1.59), P = 0.148 
L/C = 1.33 (1.02 – 1.73), P = 0.036 
A/C = 1.15 (0.95 – 1.40), P = 0.161 
L/C = 1.15 (0.94 – 1.40), P = 0.171 
 
Abbreviations: A, amlodipine; C, chlorthalidone; L, lisinopril 
*Adjusted for age, race, gender, diabetes, prevalent cardiovascular dise se (CVD), baseline glomerular 
filtration rate (eGFR), body mass index (BMI) and smoking. 
 
 








 Hazard ratio (95% CI), P Hazard ratio (95% CI), P 
Unadjusted A/C = 1.23 (0.93 - 1.63), P = 0.14 
L/C = 1.34 (1.02 - 1.76), P = 0.04 
A/C = 1.16 (0.96 - 1.41), P = 0.12 
L/C = 1.12 (0.92 - 1.36), P = 0.25 
Adjusted* A/C = 1.21 (0.91 - 1.62), P = 0.19 
L/C = 1.39 (1.05 - 1.84), P = 0.02 
A/C = 1.15 (0.94 - 1.40), P = 0.18 
L/C = 1.16 (0.95 - 1.43), P = 0.15 
Abbreviations: A, Amlodipine; C, chlorthalidone; L, Lisinopril 
*Adjusted for age, race, gender, diabetes, baseline or at year 1 estimated glomerular filtration ratio (eGFR), 
incident at year 1 and prevalent cardiovascular disease, body mass index, and smoking. 
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eFigure 2. Kaplan-Meier Curves for Hip and Pelvic Fractures for the In-Trial Cohort in the Chlorthalidone 
Group by Atenolol Use at 1 Month 
 
 
 Hazard ratio (95% CI), P 
Unadjusted 1.43 (0.67 – 3.07), P = 0.352 
Adjusted* 1.29 (0.56 – 2.95), P = 0.548 
*Adjusted for age, race, gender, diabetes, baseline estimated glomerular fi tration ratio (eGFR), prevalent 
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eFigure 3. Adjusted In-Trial Hazard Ratios for Hip or Pelvic Fracture in Those Randomized to 
Chlorthalidone Compared With Amlodipine or Chlothalidone Compared With Lisinopril, by Various 




Abbreviations: BL, baseline; CKD, chronic kidney disease; CVD, cardiovascular disease; DM, diabetes 
mellitus; GFR, glomerular filtration rate; MDRD, modification of diet in renal disease; Prv, prevalent; Yr, 
year. 
 
*Adjusted for age, race, gender, diabetes, baseline estimated glomerular filtration rate (eGFR), prevalent 
cardiovascular disease, body mass index (BMI) and smoking. 
 
†For estrogen, women only. 
 
 
